Photo from Piet Ost/X
May 8, 2024, 02:11
Piet Ost: RADIOSA trial at ESTRO24
Piet Ost, Assistant Professor of Radiation Oncology at Ghent University, shared on X/Twitter:
“RADIOSA trial:
- oligorecurrent PCa SBRT vs SBRT + 6 months ADT
- ADT improved bRFS and cRFS
- more polymetastatic recurrences in the ADT arm.
- would love to see eugonad-relapse free survival.
- will be interesting to see QoL data and compare with the DART trial.
ESTRO24.”
Source: Piet Ost/X
May 19, 2024, 16:28